Medtronic plc announced two U.S. Food and Drug Administration (FDA) regulatory milestones for its MiniMed™ 780G system. The SmartGuard™ algorithm received clearance as an interoperable automated glycemic controller (iAGC), enabling integration with the Instinct sensor, made by Abbott, for type 1 diabetes.
Separately, the FDA approved the MiniMed™ 780G system for use in adults 18 years and older with insulin-requiring type 2 diabetes. This makes it the first and only automated insulin delivery (AID) system with Meal Detection™ technology available to this population, aligning with ADA Standards of Care.
The Instinct sensor, designed exclusively by Abbott for MiniMed™ systems, is the world's smallest, thinnest, and most discreet integrated CGM, offering a wear time of up to 15 days. These milestones significantly broaden the MiniMed™ 780G system's portfolio, providing greater choice and flexibility for a wider range of diabetes patients and advancing Medtronic's smart dosing ecosystem.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.